At Nuclera, we’re driven by a single goal: to revolutionize protein expression and optimization. That’s why we’re excited to share news of our latest collaboration with Cytiva, a global leader in life sciences. Together, we’re streamlining the production, purification, and characterization of proteins essential for drug research and development—bringing new efficiencies to a process that has traditionally taken months.
This collaboration integrates our benchtop eProtein Discovery™ System with Cytiva’s renowned Biacore™ surface plasmon resonance (SPR) technology. The result? The ability to go from protein expression to characterization in just five days.
Proteins account for 95% of drug targets, making rapid access to high-quality protein samples critical to developing treatments that combat disease. At industry-leading conferences like Discovery on Target and PEGS Europe, we demonstrated this powerful combination in action. Using the eProtein Discovery System, we successfully produced Bruton’s Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF)—two clinically relevant proteins. These were then functionally characterized using Cytiva’s Biacore SPR system, validating both speed and scientific rigor.
As Dr. Yvonne Tan, our Associate Director of Product, put it:
“Collaborating with life science leader Cytiva supports Nuclera in our mission of improving human health. Through this collaboration, we have demonstrated eProtein Discovery’s ability to produce clinically significant proteins that can be used in characterization experiments. Combining eProtein Discovery’s capability to streamline protein production workflows with Cytiva’s Biacore protein characterization systems open a whole new avenue for accelerating drug development.”
Anna Moberg, Senior Manager and Project Manager at Cytiva, also shared her excitement:
“The ability of Nuclera’s eProtein Discovery to accelerate protein production and purification complements Cytiva’s Biacore SPR technology by streamlining the upstream protein production process. We look forward to continuing our collaboration to further enhance the production of characterizable proteins for drug development.”
We believe this partnership marks a major step forward for the drug development community—and for the future of personalized, efficient therapeutics.
Learn more about how our eProtein Discovery System can accelerate your protein workflows.
